Chapter VI.2. Classes of Psychotropicsa Overview of Evidence from Clinical Trials

  1. Nawab Qizilbash MBChB, MRCP, MSc, DPhil (Oxon)1,2
  1. Brian A. Lawlor,
  2. Gregory Swanwick,
  3. Louise Carrier and
  4. Pierre Tariot

Published Online: 14 JAN 2008

DOI: 10.1002/9780470752340.ch41

Evidence-based Dementia Practice

Evidence-based Dementia Practice

How to Cite

Lawlor, B. A., Swanwick, G., Carrier, L. and Tariot, P. (2003) Classes of Psychotropicsa Overview of Evidence from Clinical Trials, in Evidence-based Dementia Practice (ed N. Qizilbash), Blackwell Science Ltd, Oxford, UK. doi: 10.1002/9780470752340.ch41

Editor Information

  1. 1

    Visiting Professor of Geriatric Medicine, Hospital Universitario GM-Cantoblanco, 280049 Madrid, Spain

  2. 2

    Member of Green College, Oxford University, Oxford, UK

Publication History

  1. Published Online: 14 JAN 2008
  2. Published Print: 1 JAN 2003

ISBN Information

Print ISBN: 9780632052967

Online ISBN: 9780470752340



  • antipsychotics;
  • behavioral disorders;
  • neuroleptics;
  • individual agents;
  • thioridazine


This chapter contains section titled:

  • Efficacy/safety of conventional antipsychotics as a group

  • Duration of treatment

  • Efficacy of individual agents

  • Benzodiazepine

  • Buspirone

  • Evidence

  • Who should be considered for treatment?

  • Adverse effects

  • Number needed to treat

  • Future research

  • Conclusions

  • Selegiline

  • Cholinesterase inhibitors

  • Evidence